Patents by Inventor Eric Stangeland

Eric Stangeland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bicyclic compounds useful as GPR120 modulators
    Patent number: 11919891
    Abstract: Provided herein are compounds, compositions including them, and methods of modulating GPR120 activity and treating diseases mediated by GPR120 by administering such compounds and compositions.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: March 5, 2024
    Assignee: Valo Health, Inc.
    Inventors: Brian Raimundo, Elena S. Koltun, John Griffin, Eric Stangeland
  • MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS
    Publication number: 20230183231
    Abstract: Provided herein are compounds, compositions including them, and methods of modulating GPR120 activity and treating diseases mediated by GPR120 by administering such compounds and compositions.
    Type: Application
    Filed: October 3, 2022
    Publication date: June 15, 2023
    Inventors: Brian Raimundo, Elena S. Koltun, John Griffin, Eric Stangeland
  • Monocyclic compounds useful as GPR120 modulators
    Patent number: 11548886
    Abstract: Provided herein are compounds, compositions including them, and methods of modulating GPR120 activity and treating diseases mediated by GPR120 by administering such compounds and compositions.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: January 10, 2023
    Assignee: Valo Health, Inc.
    Inventors: Brian Raimundo, Elena S. Koltun, John Griffin, Eric Stangeland
  • BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS
    Publication number: 20210347768
    Abstract: Provided herein are compounds, compositions including them, and methods of modulating GPR120 activity and treating diseases mediated by GPR120 by administering such compounds and compositions.
    Type: Application
    Filed: December 14, 2020
    Publication date: November 11, 2021
    Inventors: Brian Raimundo, Elena S. Koltun, John Griffin, Eric Stangeland
  • MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS
    Publication number: 20210101896
    Abstract: Provided herein are compounds, compositions including them, and methods of modulating GPR120 activity and treating diseases mediated by GPR120 by administering such compounds and compositions.
    Type: Application
    Filed: August 20, 2020
    Publication date: April 8, 2021
    Inventors: Brian Raimundo, Elena S. Koltun, John Griffin, Eric Stangeland
  • Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity
    Publication number: 20210024493
    Abstract: A method of treating a pulmonary disorder in a patient, comprising administering a pharmaceutical composition comprising an isotonic aqueous solution comprising a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the pulmonary disorder is asthma or chronic obstructive pulmonary disorder.
    Type: Application
    Filed: October 8, 2020
    Publication date: January 28, 2021
    Inventors: Adam D. HUGHES, Daniel BYUN, Yan CHEN, Melissa FLEURY, John R. JACOBSEN, Eric STANGELAND, Richard D. WILSON, Rose YEN
  • Bicyclic compounds useful as GPR120 modulators
    Patent number: 10865201
    Abstract: Provided herein are compounds, compositions including them, and methods of modulating GPR120 activity and treating diseases mediated by GPR120 by administering such compounds and compositions.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: December 15, 2020
    Assignee: Valo Health, Inc.
    Inventors: Brian Raimundo, Elena S. Koltun, John Griffin, Eric Stangeland
  • Diamide compounds having muscarinic receptor antagonist and ?2 adrenergic receptor agonist activity
    Patent number: 10836744
    Abstract: The invention relates to a pharmaceutical composition comprising an isotonic aqueous solution comprising a compound of formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: November 17, 2020
    Assignee: Theravance Respiratory Company, LLC
    Inventors: Adam D. Hughes, Daniel Byun, Yan Chen, Melissa Fleury, John R. Jacobsen, Eric Stangeland, Richard D. Wilson, Rose Yen
  • Monocyclic compounds useful as GPR120 modulators
    Patent number: 10800773
    Abstract: Provided herein are compounds, compositions including them, and methods of modulating GPR120 activity and treating diseases mediated by GPR120 by administering such compounds and compositions.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: October 13, 2020
    Assignee: Integral Health, Inc.
    Inventors: Brian Raimundo, Elena S. Koltun, John Griffin, Eric Stangeland
  • Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity
    Publication number: 20200165223
    Abstract: The invention relates to a pharmaceutical composition comprising an isotonic aqueous solution comprising a compound of formula I: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 28, 2020
    Publication date: May 28, 2020
    Inventors: Adam D. HUGHES, Daniel BYUN, Yan CHEN, Melissa FLEURY, John R. JACOBSEN, Eric STANGELAND, Richard D. WILSON, Rose YEN
  • Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity
    Patent number: 10590107
    Abstract: The invention relates to a pharmaceutical composition comprising an isotonic aqueous solution comprising a compound of formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: March 17, 2020
    Assignee: Theravance Respiratory Company, LLC
    Inventors: Adam D. Hughes, Daniel Byun, Yan Chen, Melissa Fleury, John R. Jacobsen, Eric Stangeland, Richard D. Wilson, Rose Yen
  • Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity
    Publication number: 20190300504
    Abstract: The invention relates to a pharmaceutical composition comprising an isotonic aqueous solution comprising a compound of formula I: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 7, 2019
    Publication date: October 3, 2019
    Inventors: Adam D. HUGHES, Daniel BYUN, Yan CHEN, Melissa FLEURY, John R. JACOBSEN, Eric STANGELAND, Richard D. WILSON, Rose YEN
  • Diamide compounds having muscarinic receptor antagonist and ?2 adrenergic receptor agonist activity
    Patent number: 10358433
    Abstract: The invention relates to a pharmaceutical composition comprising an isotonic aqueous solution comprising from about 0.05 ?g/mL to about 10 mg/mL of a compound of formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: July 23, 2019
    Assignee: Theravance Respiratory Company, LLC
    Inventors: Adam D. Hughes, Daniel Byun, Yan Chen, Melissa Fleury, John R. Jacobsen, Eric Stangeland, Richard D. Wilson, Rose Yen
  • BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS
    Publication number: 20190218208
    Abstract: Provided herein are compounds, compositions including them, and methods of modulating GPR120 activity and treating diseases mediated by GPR120 by administering such compounds and compositions.
    Type: Application
    Filed: September 11, 2017
    Publication date: July 18, 2019
    Inventors: Brian Raimundo, Elena S. Koltun, John Griffin, Eric Stangeland
  • MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS
    Publication number: 20190202821
    Abstract: Provided herein are compounds, compositions including them, and methods of modulating GPR120 activity and treating diseases mediated by GPR120 by administering such compounds and compositions.
    Type: Application
    Filed: September 11, 2017
    Publication date: July 4, 2019
    Inventors: Brian Raimundo, Elena S. Koltun, John Griffin, Eric Stangeland
  • Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity
    Publication number: 20190047984
    Abstract: The invention relates to a pharmaceutical composition comprising an isotonic aqueous solution comprising from about 0.05 ?g/mL to about 10 mg/mL of a compound of formula I: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 15, 2018
    Publication date: February 14, 2019
    Inventors: Adam D. HUGHES, Daniel BYUN, Yan CHEN, Melissa FLEURY, John R. JACOBSEN, Eric STANGELAND, Richard D. WILSON, Rose YEN
  • 3-phenoxymethylpyrrolidine compounds
    Patent number: 9227933
    Abstract: In one aspect, the invention relates to compounds of formula I: where R1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: January 5, 2016
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Eric Stangeland, Daisuke Roland Saito, Priscilla Van Dyke, Lori Jean Patterson
  • 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS
    Publication number: 20150126577
    Abstract: In one aspect, the invention relates to compounds of formula I: where R1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Application
    Filed: January 12, 2015
    Publication date: May 7, 2015
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Eric Stangeland, Daisuke Roland Saito, Priscilla Van Dyke, Lori Jean Patterson
  • 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS
    Publication number: 20130178509
    Abstract: In one aspect, the invention relates to compounds of formula I: where a and R1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    Type: Application
    Filed: June 27, 2012
    Publication date: July 11, 2013
    Applicant: THERAVANCE, INC.
    Inventors: Eric Stangeland, Priscilla Van Dyke, Timothy J. Church, Lori Jean Patterson, Daisuke Roland Saito
  • BIPHENYL DERIVATIVES
    Publication number: 20130150404
    Abstract: This invention provides biphenyl derivatives of formula I: wherein R1, R2, R3, R4, R5, R6, R7, W, a, b and c are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The biphenyl derivatives of this invention possess both ?2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl derivatives are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthmas.
    Type: Application
    Filed: July 10, 2012
    Publication date: June 13, 2013
    Applicant: THERAVANCE, INC.
    Inventors: Mathai Mammen, Sarah Dunham, Adam Hughes, Craig Husfeld, Eric Stangeland